Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix (OCUL) has 5 years of Convertible Debt data on record, last reported at $9.1 million in Q4 2023.

  • For Q4 2023, Convertible Debt fell 68.21% year-over-year to $9.1 million; the TTM value through Dec 2023 reached $9.1 million, down 68.21%, while the annual FY2023 figure was $9.1 million, 68.21% down from the prior year.
  • Convertible Debt reached $9.1 million in Q4 2023 per OCUL's latest filing, up from $8.8 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $30.0 million in Q2 2023 and bottomed at $8.8 million in Q3 2023.
  • Average Convertible Debt over 5 years is $24.3 million, with a median of $25.3 million recorded in 2020.
  • Peak YoY movement for Convertible Debt: increased 10.27% in 2020, then tumbled 68.87% in 2023.
  • A 5-year view of Convertible Debt shows it stood at $24.3 million in 2019, then rose by 0.01% to $24.3 million in 2020, then grew by 8.75% to $26.4 million in 2021, then increased by 8.75% to $28.7 million in 2022, then plummeted by 68.21% to $9.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $9.1 million in Q4 2023, $8.8 million in Q3 2023, and $30.0 million in Q2 2023.